Stock Groups

Novavax tumbles after Politico report on COVID-19 vaccine production delay -Breaking


© Reuters. FILE PHOTO: A vial and sryinge are seen in front of a displayed Novavax logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration

(Reuters) – Shares of Novavax (NASDAQ:) Inc fell 20% after a report from Politico said the company faces significant hurdles in proving it can manufacture its experimental COVID-19 vaccine that meets regulators’ quality standards, resulting in production delays.

The methods Novavax used to test the purity of its vaccine have fallen short of U.S. regulators’ standards, according to the Politico report, citing people familiar with the matter.

Novavax in a statement said it was confident in its ability to deliver its high-quality vaccine.

“We underscore our ongoing commitment to the stringent standards of production and manufacturing for our recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant,” the company said.

The company said it has filed for regulatory authorization for its shot in India, Indonesia and the Philippines and reiterated that it expects to file for emergency use authorization in the United States before the end of 2021.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



Mike Robinson
Mike covers the financial, utilities and biotechnology sectors for Street Register. He has been writing about investment and personal finance topics for almost 12 years. Mike has an MBA in Finance from Wake Forest University.